咖啡因及其相关代谢物与LRRK2突变携带者帕金森病抵抗性的关联:一项代谢组学研究
该研究对LRRK2队列联盟中368例帕金森病患者和未患病对照(含LRRK2突变携带者与非携带者)进行血浆及部分脑脊液代谢组学分析,发现血浆咖啡因浓度在帕金森病患者中较低,尤其在LRRK2突变携带者中降低更明显(76% vs 31%),且LRRK2状态与帕金森病状态存在显著交互作用(p=0.005)。咖啡因代谢物及葫芦巴碱也呈现类似结果,提示这些代谢物可能是LRRK2相关帕金森病抵抗性的标志物。
要点
- LRRK2突变携带者中,帕金森病患者血浆咖啡因浓度比未患病对照低76%,而非携带者中仅低31%。
- 咖啡因、其去甲基化代谢物(副黄嘌呤、茶碱、1-甲基黄嘌呤)及葫芦巴碱均与帕金森病抵抗性相关。
- LRRK2状态与帕金森病状态对咖啡因及其代谢物存在显著交互作用(p=0.005)。
核心结论
- 咖啡因及其去甲基化代谢物和葫芦巴碱是LRRK2突变相关帕金森病抵抗性的突出标志物,其关联性强于特发性帕金森病。
研究设计与样本
- 研究纳入LRRK2队列联盟的368例帕金森病患者和未患病对照,包括118例LRRK2+/PD+、115例LRRK2+/UC、70例LRRK2-/PD+和65例LRRK2-/UC,其中68例有脑脊液样本。
- 采用液相色谱-质谱法分析血浆和脑脊液中的282种分析物,使用协方差分析模型校正年龄、研究站点队列和性别,并进行多重比较校正。
主要发现
- 血浆咖啡因浓度在帕金森病患者中低于未患病对照(p < 0.001),在LRRK2+携带者中降低76%,在LRRK2-参与者中降低31%,LRRK2与帕金森病状态交互作用显著(p = 0.005)。
- 血浆中咖啡因代谢物(副黄嘌呤、茶碱、1-甲基黄嘌呤)及咖啡消费的非黄嘌呤标志物葫芦巴碱呈现类似结果,脑脊液子集样本结果一致。
- LRRK2+/PD+患者的膳食咖啡因摄入量低于LRRK2+/UC,与LRRK2+突变存在显著交互作用(p < 0.001)。
关键数值与推荐
- 血浆咖啡因浓度在帕金森病患者与未患病对照间的差异具有统计学显著性(p < 0.001)。
- LRRK2状态与帕金森病状态对血浆咖啡因浓度的交互作用显著(p = 0.005)。
- 膳食咖啡因摄入量与LRRK2+突变的交互作用显著(p < 0.001)。
临床怎么用
- 对于LRRK2突变携带者,较低的血浆咖啡因及其代谢物水平可能与帕金森病风险相关,但需进一步验证。
- 咖啡因及其代谢物可作为LRRK2相关帕金森病抵抗性的潜在生物标志物,但尚不能用于临床预测。
局限性
- 研究为横断面设计,无法确定咖啡因及其代谢物与帕金森病抵抗性的因果关系。
- 部分分析物仅在子集样本(68例)的脑脊液中检测,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify markers of resistance to developing Parkinson disease (PD) among LRRK2 mutation carriers (LRRK2+), we carried out metabolomic profiling in individuals with PD and unaffected controls (UC), with and without the LRRK2 mutation. METHODS: Plasma from 368 patients with PD and UC in the LRRK2 Cohort Consortium (LCC), comprising 118 LRRK2+/PD+, 115 LRRK2+/UC, 70 LRRK2-/PD+, and 65 LRRK2-/UC, and CSF available from 68 of them, were analyzed by liquid chromatography with mass spectrometry. For 282 analytes quantified in plasma and CSF, we assessed differences among the 4 groups and interactions between LRRK2 and PD status, using analysis of covariance models adjusted by age, study site cohort, and sex, with p value corrections for multiple comparisons. RESULTS: Plasma caffeine concentration was lower in patients with PD vs UC (p < 0.001), more so among LRRK2+ carriers (by 76%) than among LRRK2- participants (by 31%), with significant interaction between LRRK2 and PD status (p = 0.005). Similar results were found for caffeine metabolites (paraxanthine, theophylline, 1-methylxanthine) and a nonxanthine marker of coffee consumption (trigonelline) in plasma, and in the subset of corresponding CSF samples. Dietary caffeine was also lower in LRRK2+/PD+ compared to LRRK2+/UC with significant interaction effect with the LRRK2+ mutation (p < 0.001). CONCLUSIONS: Metabolomic analyses of the LCC samples identified caffeine, its demethylation metabolites, and trigonelline as prominent markers of resistance to PD linked to pathogenic LRRK2 mutations, more so than to idiopathic PD. Because these analytes are known both as correlates of coffee consumption and as neuroprotectants in animal PD models, the findings may reflect their avoidance by those predisposed to develop PD or their protective effects among LRRK2 mutation carriers.
引用
- Crotty GF, Maciuca R, Macklin EA, et al. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology. 2020. PMID: 32999056. doi:10.1212/WNL.0000000000010863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。